On the extrapolation from animal models to human disease for the design of immunotherapy in autoimmune diabetes

  • Jean-François Bach


Type 1 diabetes, insulin-dependent diabetes mellitus (IDDM) is a T-cell-mediated autoimmune disease (Bach 1994). It is thus logical to attempt to stop or better prevent disease progression by immunotherapy. A multitude of immunological treatments have been shown to be successful in the most currently available model of type 1 diabetes, namely, the nonobese diabetic (NOD) mouse. This observation may be taken in a positive fashion, paving the way for testing these strategies in humans. Conversely, one may wonder whether the NOD mouse is not, in some ways, “too sensitive” to immunological intervention, rendering the extrapolation of results obtained in NOD mice to human diabetes uncertain. This is, in fact, a very complex question which shall be addressed in some detail below.


Glutamic Acid Decarboxylase Nonobese Diabetic Mouse Antilymphocyte Serum Positive Fashion Kampo Formulation 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Bach J-F (1994) Insulin-dependent diabetes mellitus as an autoimmune disease. Endocrine Rev 15: 516–542Google Scholar
  2. Bach J-F (1998) The natural history of islet-specific autoimmunity in NOD mice. In: Leiter E, Atkinson M (eds) NOD mice and related strains: research applications in diabetes, AIDS, cancer and other diseases. RG Landes, Austin, Tex, pp 121–144Google Scholar
  3. Bach J-F (2001) Protective role of infections and vaccinations on autoimmune diseases. J Autoimmun 16: 347–353PubMedCrossRefGoogle Scholar
  4. Bach J-F, Chatenoud L (2001) Tolerance to islet autoantigens and type I diabetes. Annu Rev Immunol 19: 131–161PubMedCrossRefGoogle Scholar
  5. Bertry-Coussot L, Lucas B, Danel Claire, Halbwachs-Mecarelli L, Bach J-F, Chatenoud L, Lemarchand P (2002) Long-term reversal of established autoimmunity upon transient blockade of the LFA-1/intercellular adhesion molecule-1 pathway. J Immunol 168: 3641–3648PubMedGoogle Scholar
  6. Canadian-European Randomized Control Trial Group (1988) Cyclosporin-induced remission of IDDM after early intervention: association of 1 yr of cyclosporin treatment with enhanced insulin secretion. Diabetes 37: 1574–1582CrossRefGoogle Scholar
  7. Chatenoud L, Thervet E, Primo J, Bach J-F (1994) Anti-CD3 antibody induces long-term remission of overt autoimmunity in nonobese diabetic mice. Proc Natl Acad Sci USA 91: 123–127PubMedCrossRefGoogle Scholar
  8. Diabetes Prevention Trial-Type 1 Diabetes Study Group (2002) Effects of insulin in relatives of patients with type 1 diabetes mellitu. N Engl J Med 346: 1685–1691CrossRefGoogle Scholar
  9. Elias D, Cohen IR (1994) Peptide therapy for diabetes in NOD mice. Lancet 343: 704–706PubMedCrossRefGoogle Scholar
  10. Feutren G, Papoz L, Assan R, Vialettes B, Karsenty G, Yexiau P, Du Rostu H, Rodier M, Sirmai J, Lallemand A, Bach J-F (1986) Cyclosporin increases the rate and length of remissions in insulin-dependent diabetes of recent onset: results of a multicentre double-blind trial. Lancet 2: 119–124PubMedCrossRefGoogle Scholar
  11. Herold KC, Hagopian W, Auger J A, Poumian-Ruiz E, Taylor L, Donaldson D, Gitelman SE, Harlan DM, Xu D, Zivin RA, Bluestone JA (2002) Anti-CD3 monoclonal antibody in new-onset type 1 diabetes mellitus. N Engl J Med 346: 1692–1698PubMedCrossRefGoogle Scholar
  12. Kim JY, Cho SH, Kim YW, Jang EC, Park SY, Kim EJ, Lee SK (1999) Effects of BCG, lymphotoxin and bee venom on insulitis and development of IDDM in non-obese diabetic mice. J Kor Med Sci 14: 648–652Google Scholar
  13. Lampeter EF, Klinghammer A, Scherbaum WA, Heinze E, Haastert B, Giani G, Kolb H (1998) The Deutsche Nicotinamide Intervention Study: an attempt to prevent type 1 diabetes: DENIS Group. Diabetes 47: 980–984PubMedCrossRefGoogle Scholar
  14. Liang L, Beshay E, Prud’Homme GJ (1998) The phosphodiesterase inhibitors pentoxifylline and rolipram prevent diabetes in NOD mice. Diabetes 47: 570–575PubMedCrossRefGoogle Scholar
  15. Maki T, Ichikawa T, Blanco R, Porter J (1992) Long-term abrogation of autoimmune diabetes in nonobese diabetic mice by immunotherapy with anti-lymphocyte serum. Proc Natl Acad Sci USA 89: 3434–3438PubMedCrossRefGoogle Scholar
  16. Miller BJ, Appel MC, O’Neil JJ, Wicker LS (1988) Both the Lyt-2+ and L3T4+ T cell subsets are required for the transfer of diabetes in nonobese diabetic mice. J Immunol 140: 52–58PubMedGoogle Scholar
  17. Pozzilli P, Visalli N, Ghirlanda G, Manna R, Andreani D (1989) Nicotinamide increases C-peptide secretion in patients with recent onset type 1 diabetes. Diabet Med 6: 568–572PubMedCrossRefGoogle Scholar
  18. Raz I, Elias D, Avron A, Tamir M, Metzger M, Cohen IR (2001) Beta-cell function in new-onset type 1 diabetes and immunomodulation with a heat-shock protein peptide (DiaPep277): a randomised, double-blind, phase II trial. Lancet 358: 1749–1753PubMedCrossRefGoogle Scholar
  19. Silverstein J, MacLaren N, Riley W, Spillar R, Radjenovic D, Johnson S (1988) Immunosuppression with azathioprine and prednisone in recent-onset insulin-dependent diabetes mellitus. N Engl J Med 319: 599–604PubMedCrossRefGoogle Scholar
  20. Toyota T, Satoh J, Oya K, Shintani S, Okano T (1986) Streptococcal preparation (OK-432) inhibits development of type I diabetes in NOD mice. Diabetes 35: 496–499PubMedGoogle Scholar
  21. Wang Y, Hao L, Gill RG, Lafferty KJ (1987) Autoimmune diabetes in NOD mouse is L3T4 T-lymphocyte dependent. Diabetes 36: 535–538PubMedCrossRefGoogle Scholar
  22. Yasunami R, Bach J-F (1988) Anti-suppressor effect of cyclophosphamide on the development of spontaneous diabetes in NOD mice. Eur J Immunol 18: 481–484PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Wien 2003

Authors and Affiliations

  • Jean-François Bach
    • 1
    • 2
  1. 1.Maladies Auto-immunesUnité de Institut National de la Santé et de la Recherche Médicale,Hôpital NeckerParisFrance
  2. 2.INSERM U25, Hôpital NeckerParis Cedex 15France

Personalised recommendations